These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24154779)

  • 21. Optimal management of chronic gout: attempting to render the (t)issues crystal-clear.
    Wong ML
    N Z Med J; 2005 Jun; 118(1217):U1533. PubMed ID: 15980907
    [No Abstract]   [Full Text] [Related]  

  • 22. [Analysis of the hypo-uricemic action of benzbromarone in 40 cases of gouty and non-gouty hyperuricemia].
    Famaey JP; Vandenabeele G
    J Belge Rhumatol Med Phys; 1970; 25(1):5-9. PubMed ID: 5486285
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
    Zöllner N; Griebsch A; Fink JK
    Dtsch Med Wochenschr; 1970 Nov; 95(48):2405-12. PubMed ID: 5480261
    [No Abstract]   [Full Text] [Related]  

  • 24. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
    Lhotta K
    Kidney Int; 2003 Nov; 64(5):1920-1. PubMed ID: 14531831
    [No Abstract]   [Full Text] [Related]  

  • 25. Emerging uricosurics for gout.
    Terkeltaub R
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):247-249. PubMed ID: 27937050
    [No Abstract]   [Full Text] [Related]  

  • 26. Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone.
    Roberts RL; Wallace MC; Wright DF; Cadzow M; Dalbeth N; Jones PB; Stamp LK; Harrison AA; Black MA; Merriman TR
    Joint Bone Spine; 2014 Mar; 81(2):160-3. PubMed ID: 23932726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benzbromarone as a long-term uricosuric agent.
    Bluestone R; Klinenberg J; Lee IK
    Adv Exp Med Biol; 1980; 122A():283-6. PubMed ID: 6999849
    [No Abstract]   [Full Text] [Related]  

  • 29. [Gout: physiopathology, diagnosis, course, treatment].
    Chazerain P; Ziza JM
    Rev Prat; 1998 Sep; 48(13):1453-6. PubMed ID: 10050628
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
    Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term management of gout: nonpharmacologic and pharmacologic therapies.
    Chaichian Y; Chohan S; Becker MA
    Rheum Dis Clin North Am; 2014 May; 40(2):357-74. PubMed ID: 24703352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacology of hypouricemic effect of benzbromarone.
    Sinclair DS; Fox IH
    J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient.
    Decaux G; Soupart A; Musch W; Hannotier P; Prospert F
    Clin Nephrol; 1998 Oct; 50(4):262-5. PubMed ID: 9799074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Summary of the Dutch College of General Practitioners' "Gout" Standard].
    Romeijnders AC; Gorter KJ
    Ned Tijdschr Geneeskd; 2002 Feb; 146(7):309-13. PubMed ID: 11876034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study".
    George J
    Circ Heart Fail; 2010 May; 3(3):e10; author reply e14. PubMed ID: 20484184
    [No Abstract]   [Full Text] [Related]  

  • 36. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fatal fulminant hepatic failure associated with benzbromarone.
    Wagayama H; Shiraki K; Sugimoto K; Fujikawa K; Shimizu A; Takase K; Nakano T; Tameda Y
    J Hepatol; 2000 May; 32(5):874. PubMed ID: 10845680
    [No Abstract]   [Full Text] [Related]  

  • 38. The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan.
    Lai SW; Liao KF; Kuo YH; Hwang BF; Liu CS
    Medicine (Baltimore); 2023 Feb; 102(5):e32779. PubMed ID: 36749254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of benzbromarone on hyperlipidemia in gout].
    Marinchev L; Kŭnev K
    Vutr Boles; 1990; 29(5):99-102. PubMed ID: 2080622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fulminant hepatic failure associated with benzbromarone treatment: a case report.
    Arai M; Yokosuka O; Fujiwara K; Kojima H; Kanda T; Hirasawa H; Saisho H
    J Gastroenterol Hepatol; 2002 May; 17(5):625-6. PubMed ID: 12084041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.